This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ehret, M. J. Search for Related Content Social Bookmarking                         What's this?

Pharmacogenomics of Antidepressant Medications

University of Connecticut, Institute of Living, Burlingame Center, Fuller Building, Room 14, 200 Retreat Ave, Hartford, CT 06106, mehret{at}harthosp.org

With the completion of the human genome project, surges in studies investigating the association of antidepressant responsiveness and select polymorphisms have been conducted. Studies have been completed investigating polymorphisms in the monoaminergic system, including the serotonin transporter gene, the serotonin 1A, 2A, and 6 receptor genes, the G-protein-coupled receptor genes, the tryptophan hydroxylase 1 gene, the monoamine oxidase gene, the dopamine receptor genes, and the noradrenergic genes. Other genes of potential interest for investigation include the nitric oxide gene, the angiotensin-converting enzyme gene, the interleukin-1 beta gene, the stress hormone system, and the phosphodiesterase genes. Many of the studies have provided positive results, but the studies are small and are limited to a specific ethnicity. Further research is needed in the area before an array of genes can be used to predetermine response to antidepressant medication.

Key Words: Antidepressants • pharmacogenomics • pharmacodynamics • depression • polymorphisms.

Journal of Pharmacy Practice, Vol. 19, No. 6, 342-352 (2006)
DOI: 10.1177/0897190007300729


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?